The biotech startup secured its Series B round, which was led by Drive Capital with participation from Chiesi Farmaceutici, GreenSky Capital and members of Cyclica’s management team. (VentureBeat)
The biotech startup secured its Series B round, which was led by Drive Capital with participation from Chiesi Farmaceutici, GreenSky Capital and members of Cyclica’s management team. (VentureBeat)
The biotech startup secured its Series B round, which was led by Drive Capital with participation from Chiesi Farmaceutici, GreenSky Capital and members of Cyclica’s management team. (VentureBeat)
Talking point: Cyclica’s drug-discovery platform leverages artificial intelligence in the biophysics space. According to the U.S. Food and Drug Administration, a new drug takes an average of 12 to 15 years and over US$2.6 billion dollars to develop—a process Cyclica hopes to decentralize by partnering with other companies and research institutions. With the support of the Ontario Centres of Excellence and IBM, the company has recently harnessed the power of supercomputers to map out a database that will help researchers identify genetic variants. The new funds will be used to forge new partnerships as well as expand its application within the pharma industry and adjacent sectors, such as agro-chemicals.
Loading...
You have shared 5 articles this month and reached the maximum amount of shares available.
CloseIf you would like to purchase a sharing license please contact The Logic support at [email protected].
CloseYou have gifted 0 article(s) this month and have 5 remaining.
Recipients will be able to read the full text of the article after submitting their email address. They will not have access to other articles or subscriber benefits.
Get up to speed in minutes with insights and analysis on the most important stories of the day, every weekday.
See the bigger picture with reporters and industry experts in subscriber-exclusive events.
Membership provides access to our popular Slack channel, participation in subscriber surveys and invitations to exclusive events with our journalists and special guests.